Compounds > clarithromycin
Page last updated: 2024-08-25

clarithromycin and opc-67683

clarithromycin has been researched along with opc-67683 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Chen, J; Ding, C; Doyle, T; Duncan, L; Ebright, RH; He, S; Lin, W; Liu, Y; Lynch, AS; Ma, Z; Molodtsov, V; Nguyen, P; Pulse, M; Robertson, GT; Wang, H; Weiss, WJ; Xu, X; Yuan, Y; Zhuang, Z1
Jo, KW; Nam, GB; Shim, TS; Yoon, HY1

Other Studies

2 other study(ies) available for clarithromycin and opc-67683

ArticleYear
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
    Journal of medicinal chemistry, 2022, 03-24, Volume: 65, Issue:6

    Topics: Anaerobiosis; DNA-Directed RNA Polymerases; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Rifamycins

2022
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017, 09-01, Volume: 21, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Azithromycin; Child; Clarithromycin; Clofazimine; Diarylquinolines; Female; Fluoroquinolones; Follow-Up Studies; Humans; Lost to Follow-Up; Macrolides; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult

2017